Cetuximab, a chimeric antibody which recognizes the extracellular EGFR domain, can be combined with first line cisplatin/vinorelbine in those subjects with advanced or recurrent NSCLC [6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.